MX2019010941A - Receptores de antigeno y usos de los mismos. - Google Patents

Receptores de antigeno y usos de los mismos.

Info

Publication number
MX2019010941A
MX2019010941A MX2019010941A MX2019010941A MX2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A
Authority
MX
Mexico
Prior art keywords
antigen receptors
express
antigen
treatment
cells
Prior art date
Application number
MX2019010941A
Other languages
English (en)
Inventor
Simon Petra
Sahin Ugur
Birtel Matthias
Holger VOSS Ralf
Caspar Janina
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of MX2019010941A publication Critical patent/MX2019010941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/30—Mixture of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención generalmente abarca el tratamiento de enfermedades al dirigir células que expresan un antígeno en la superficie celular. En particular, la invención se refiere a receptores de antígeno recombinante y usos de los mismos. Las células T diseñadas para expresar tales receptores de antígeno son útiles en el tratamiento de enfermedades caracterizadas por la expresión de uno o más antígenos unidos por los receptores de antígeno.
MX2019010941A 2017-03-15 2018-03-14 Receptores de antigeno y usos de los mismos. MX2019010941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/056086 WO2018166589A1 (en) 2017-03-15 2017-03-15 Antigen receptors and uses thereof
PCT/EP2018/056399 WO2018167151A1 (en) 2017-03-15 2018-03-14 Antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019010941A true MX2019010941A (es) 2019-12-19

Family

ID=58360981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010941A MX2019010941A (es) 2017-03-15 2018-03-14 Receptores de antigeno y usos de los mismos.

Country Status (15)

Country Link
US (1) US11702631B2 (es)
EP (1) EP3596113B1 (es)
JP (1) JP7073417B2 (es)
KR (1) KR102396925B1 (es)
CN (1) CN110621693B (es)
AU (1) AU2018234068B2 (es)
BR (1) BR112019018705A2 (es)
CA (1) CA3054253A1 (es)
ES (1) ES2886189T3 (es)
IL (1) IL269213B2 (es)
MX (1) MX2019010941A (es)
NZ (1) NZ756383A (es)
SG (1) SG11201907715YA (es)
WO (2) WO2018166589A1 (es)
ZA (1) ZA201905441B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
CA3145223A1 (en) 2019-07-23 2021-01-28 Wen Yang Composition and method for adoptive immunotherapy
CN118139897A (zh) * 2021-11-05 2024-06-04 清华大学 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409577A (en) 1966-07-06 1968-11-05 Owens Corning Fiberglass Corp Method of detackifying tacky resins
WO2000023087A1 (en) * 1998-10-21 2000-04-27 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK2160401T3 (da) * 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
EP2502934B1 (en) * 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof

Also Published As

Publication number Publication date
US20200063101A1 (en) 2020-02-27
JP7073417B2 (ja) 2022-05-23
IL269213B1 (en) 2023-07-01
JP2020509783A (ja) 2020-04-02
EP3596113A1 (en) 2020-01-22
ZA201905441B (en) 2020-11-25
CN110621693A (zh) 2019-12-27
EP3596113B1 (en) 2021-08-04
BR112019018705A2 (pt) 2020-04-07
IL269213B2 (en) 2023-11-01
CN110621693B (zh) 2024-01-12
RU2019125594A3 (es) 2021-06-09
RU2019125594A (ru) 2021-04-15
KR20190128683A (ko) 2019-11-18
ES2886189T3 (es) 2021-12-16
IL269213A (en) 2019-11-28
US11702631B2 (en) 2023-07-18
WO2018167151A1 (en) 2018-09-20
NZ756383A (en) 2023-03-31
CA3054253A1 (en) 2018-09-20
AU2018234068B2 (en) 2021-10-21
KR102396925B1 (ko) 2022-05-13
WO2018166589A1 (en) 2018-09-20
SG11201907715YA (en) 2019-09-27
AU2018234068A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
MX378368B (es) Receptores de antigeno y usos de los mismos.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
CO2017000510A2 (es) Constructos de car
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
CO2017012971A2 (es) Anticuerpos de unión a tau
CO2017001561A2 (es) Anticuerpos anti tigit
CL2024002173A1 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteínas de las mismas
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
MX2017002459A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2017003426A (es) Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc).